MotherToBaby
Medications & More During Pregnancy & Breastfeeding
Ask The Experts

DID YOUR PATIENT WITH HIGH CHOLESTEROL, FH*, OR ASCVD* BECOME PREGNANT?

MOTHERTOBABY IS ACCEPTING REFERRALS FOR A PREGNANCY REGISTRY STUDY IN WOMEN EXPOSED AND NOT EXPOSED TO REPATHA® (EVOLOCUMAB)

MotherToBaby depends on healthcare professionals like you to provide referrals to our pregnancy studies. Our studies are observational; participants are not asked to make any changes to their healthcare routine.

Women may qualify for this study if they reside in the U.S. or Canada. We are enrolling women with hypercholesterolemia associated with FH or ASCVD **who have** and those **who have not** used evolocumab in a current or recent pregnancy.

Refer your patients by visiting **MotherToBaby.org or by calling 877.311.8972** to speak directly with a member of our research team. We are available: Monday-Friday 7:30am-6pm PST.

THIS IS AN INVESTIGATIONAL STUDY OF EVOLOCUMAB SPONSORED BY AMGEN

**Familial Hypercholesterolemia (FH), Atherosclerotic Cardiovascular Disease (ASCVD)*

MotherToBaby

Medications & More During Pregnancy & Breastfeeding
Ask The Experts

WHO IS MOTHERTOBABY?

MotherToBaby Pregnancy Studies are conducted by the non-profit Organization of Teratology Information Specialists (OTIS), the nation's leading authority on the safety of medications and other exposures during pregnancy and lactation, and are coordinated at the University of California, San Diego, CA.

MotherToBaby is dedicated to providing evidence-based information to mothers, healthcare professionals and the general public about medications and other exposures during pregnancy and while breastfeeding.

FOR MORE INFORMATION ABOUT MEDICATION USE OR OTHER ENVIRONMENTAL EXPOSURES IN PREGNANCY AND WHILE BREASTFEEDING:

Visit | MotherToBaby.org
Email | MotherToBaby@ucsd.edu
Call | 877.311.8972

Study Cohort Overview

group I

Women diagnosed with hypercholesterolemia associated with FH or ASCVD who were exposed to evolocumab during a current pregnancy.

group II

Women diagnosed with hypercholesterolemia associated with FH or ASCVD who were not exposed to a PCSK9 inhibitor during a current pregnancy.

group III

Women who have not been diagnosed with hypercholesterolemia associated with FH or ASCVD and who were not exposed to a PCSK9 inhibitor during a current pregnancy.

group IV (case series)

Women who were exposed to evolocumab during a current or recent pregnancy but who do not fulfill eligibility criteria for Group 1 (e.g., retrospective pregnancy report).

www.clinicaltrials.gov (Identifier: NCT02957604)